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We investigated the long-term prognosis of borderline ovarian tumours and determined risk factors for recurrence. One hundred
and twenty-one borderline ovarian tumours treated between 1994 and 2003 at the participating institutions in the Tohoku
Gynecologic Cancer Unit were retrospectively investigated for clinical stage, histopathological subtype, surgical technique,
postoperative chemotherapy, the presence or absence of recurrence, and prognosis. The median follow-up period was 57 months
(1–126 months). One hundred and nine cases (90.6%) were at clinical stage I. The histopathological subtypes consisted of 91 cases
of mucinous tumour (75.2%), 27 cases of serous tumour (22.3%), and three cases of endometrioid tumour. Conservative surgery was
used in 53 cases (43.8%), radical surgery in 68 cases (56.2%), a staging laparotomy in 43 cases (35.5%), and postoperative adjuvant
therapy in 30 cases (24.8%). Recurrence was found in eight cases, but no tumour-related deaths were reported. Although no
significant difference in disease-free survival rate was seen between different clinical stages, the difference in disease-free survival rate
between serous and nonserous (mucinous and endometrioid) types was significant (Po0.05). The 10-year disease-free survival rate
was 89.1% for the radical surgery group and 57.4% for the conservative surgery group – this difference was significant (Po0.05). In
the conservative surgery group, cystectomy and serous tumour were independent risk factors for recurrence. Although recurrence
was observed, the long-term prognosis of borderline ovarian tumour was favourable, without tumour-related deaths. Considering the
favourable prognosis, conservative surgery can be chosen as far as the patient has a nonserous tumour and receive adnexectomy.
However, in cases of serous type and/or receiving cystectomy special care should be given as relative risk rates of recurrence elevate
by 2–4-folds.
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Taylor (1929) found that some epithelial ovarian tumours showed
clinically intermediate behaviour between benign and malignant,
and called them ‘semimalignant’. The International Federation of
Gynecology and Obstetrics (FIGO) has formally introduced this
concept as ‘carcinoma of low malignant potential’ in 1971, and the
World Health Organization (WHO) as ‘borderline tumour’ in 1973,
when the histological diagnostic criteria was proposed. The
concept of borderline ovarian tumours was histologically defined
as a disease entity that had been proposed clinically, and the
adequacy of this histological definition has been repeatedly
verified clinically.
With an accumulated experience and knowledge regarding
the characteristics and management of borderline ovarian
tumours, reclassification and redefinition have been attempted
(Seidman and Kurman, 1996), and new prognostic factors have
been proposed (de Nictolis et al, 1992; Gershenson et al, 1999). At
present, many conflicting reports are causing confusion. As many
of the patients are relatively young (Harris et al, 1992),
preservation of fertility has been attempted with favourable results
(Morice et al, 2001). However, there are also reports of recurrence
or poor prognosis (Kaern et al, 1993; Gilks, 2003), and more
precise prognostic factors are required. We believe that it is
important to get a clear picture of the present status of borderline
ovarian tumours, as it has been more than 30 years since the
introduction of the concept of these tumours. Our retrospective
multicentre study conducted an overall clinical analysis of
borderline ovarian tumours. Our ultimate aim is to investigate
the long-term prognosis of borderline ovarian tumours, and to
determine the risk factors for recurrence.
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Information on 124 patients with a diagnosis of epithelial
borderline ovarian tumour who were treated at the Tohoku
Gynecologic Cancer Unit consisting of eight institutes from 1994 to
2003 was collected using each institutional databases.
Central pathological review was adopted in this study. One of
the authors reviewed 124 cases diagnosed by the gynaecological
pathologists of each institutes concerning histologic typing and
grading of the primary lesion and 121 cases of those were
determined as an epithelial borderline tumour. The histopatho-
logic criteria embodied in a recent conference with published
commentaries (Bell et al, 2004; Ronnett et al, 2004), some of which
are included in the current WHO classification of ovarian tumours
(Tavassoli and Devilee, 2003) were used for the diagnosis of
borderline ovarian tumours in this study. These tumours were
staged according to FIGO criteria (1987).
Radical surgery was defined as hysterectomy with bilateral
salpingo-oophorectomy. Conservative surgery was defined as any
surgery that preserved the uterus and one or both ovaries.
Conservative surgical procedure was performed as cystectomy or
adnexectomy. Peritoneal cytology was performed systematically in
both surgical procedures. Surgical staging in the present study was
defined as including peritoneal cytology, omentectomy, and pelvic
lymphadenectomy with or without paraaortic exploration (lympha-
denectomy or biopsy or palpation), and peritoneal biopsy in
radical or conservative surgery on occasion. These surgical
procedures were performed depending on the surgical teams
who provided the treatment and whether borderline tumour was
diagnosed during or after the surgical procedure.
With regard to adjuvant chemotherapy, all women with
advanced disease, those with stage Ic, and those with a likely
persistence of residual tumour after cystectomy received platinum-
based treatment in the early years of this study. Thereafter,
chemotherapy was usually confined to women with advanced
disease.
Comparisons of categorical variables were conduced by two-
tailed w
2 and Fisher’s exact tests where appropriate. Evaluation of
independent factors predicting disease-specific recurrence was
conducted by nominal logistic regression analysis. Survival
estimates were calculated using the Kaplan–Meier product limit
method. Comparison between survival curves was made using the
generalised Wilcoxon’s test. Statistical significance was set at
Po0.05. The patients who lost to follow-up were censored from the
survival data.
Detailed information regarding patient’s characteristics, treat-
ment method, recurrence, and prognosis of the disease was
abstracted from the medical record. We did not request
institutional review board approval for this study because of its
retrospective nature.
RESULTS
The median age of patients was 43 years old (range 15–76 years).
Fifty-one patients (42.1%) were below 40 years of age, and 29
Table 1 Clinical and histopathologic characteristics of patients with borderline tumours
Alive with NED Recurrence Died of disease Died of ICD Lost Total
Number of patients 94 8 0 2 17 121
Age (years)
o20 7 0 0 0 0 7
20–30 14 1 0 0 4 19
31–40 19 4 0 0 2 25
41–50 14 1 0 0 2 17
51–60 17 1 0 1 5 24
4 60 23 1 0 1 4 29
Histological type
Mucinous 73 4 0 2 12 91
Serous 19 4 0 0 4 27
Endometriod 2 0 0 0 1 3
Stage
Ia 62 4 0 2 10 78
Ib 1 0 0 0 0 1
Ic 24 3 0 0 3 30
II 2 0 0 0 0 2
IIIa 0 1 0 0 1 2
IIIb 1 0 0 0 1 2
IIIc 3 0 0 0 1 4
IV 1 0 0 0 0 1
Unknown 0 0 0 0 1 1
Surgical procedure
Radical 57 2 0 2 7 68
Conservative 37 6 0 0 10 53
Staging laparotomy
Staged 36 3 0 1 3 43
Unstaged 58 5 0 1 14 78
Adjuvant chemotherapy
Yes 22 4 0 1 3 30
No 72 4 0 1 14 91
NED¼no evidence of disease; ICD¼intercurrent disease.
Clinical outcome in borderline ovarian tumours
Y Yokoyama et al
1587
British Journal of Cancer (2006) 94(11), 1586–1591 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
spatients (24.0%) were above 60 years of age (Table 1). The follow-
up period varied from 1 to 126 months, with a median of 57
months. One hundred and nine patients (90.6%) had stage I
disease, two had stage II disease, and nine had stage III and IV
disease (Table 1). The dominant histopathological subtypes were
mucinous (91 cases; 75.2%) and serous (27 cases; 22.3%) (Table 1).
Only three tumours (2.5%) were of endometrioid type. Seventy-
five (82.4%) and 16 of the 91 mucinous borderline tumours were
intestinal and endocervical types, respectively. Radical treatment
was performed in 68 (56.2%) patients, and 53 (43.8%) patients
underwent conservative management (Table 1). Complete surgical
staging was performed in 43 (35.5%) patients (Table 1). Adjuvant
chemotherapy was given to 30 (24.8%) patients (Table 1).
Seventeen patients were lost to follow-up, and two patients died
of the other diseases (Table 1). Four patients had a mucinous
tumour with pseudomyxoma peritonei and were excluded from the
present study because presence of pseudomyxoma peritonei
changes the scope of management and the category of pseudo-
myxoma peritonei is recognised as tumour that can simulate
primary mucinous borderline ovarian tumour (Ronnett et al,
2004).
Among 102 patients who were finally evaluated for clinical
outcome and prognostic factors, eight had tumour recurrence but
none of them died of the disease (Table 1). The median time to
recurrence was 46733 months (range 14–107 months). The 5- and
10-year disease-free survival rates were 91.7 and 69.2% for stage I
diseases, respectively, and the 5- and 7-year disease-free survival
rates were 100 and 66.7% for stage II–IV diseases, respectively
(Figure 1A). The 10-year disease-free survival rate was 91.5 and
36.0% for mucinous and serous tumours, respectively (Figure 1B).
Although no significant differences in disease-free survival rate
were seen between different clinical stages, the difference between
serous and nonserous (mucinous and endometrioid) types was
significant. On the other hand, the 10-year disease-free survival
rate was 89.1% for the radical surgery group and 57.4% for the
conservative surgery group (Figure 1C). This difference was
significant (Po0.05). In univariate analysis, serous type and
conservative surgery were found to be important variables
affecting recurrence of disease (Table 2). Frequency of recurrence
was not influenced by clinical stage, staging laparotomy, and
postoperative adjuvant chemotherapy (Table 2). Multivariate
analysis showed that only conservative surgery had independent
prognostic value regarding recurrence of disease (Hazard ratio 2.2,
95% confidence interval, 0.02–0.52) (Table 2). Subsequently, risk
factors for recurrence were evaluated among 43 patients who
underwent conservative surgery (Table 3). Of these patients, six
had tumour recurrence (Table 3). Three of eight patients who had
cystectomy and three of 35 patients who had adnexectomy
experienced tumour recurrence (Table 3, Po0.03). Recurrence
occurred more frequently in patients with serous tumour than with
nonserous tumour (Table 3). No correlation was found between
recurrence and the factors such as clinical stage, staging
laparotomy, or postoperative adjuvant chemotherapy among
conservative surgery group (Table 3). Multivariate analysis
confirmed cystectomy and serous type as an independent risk
factor for recurrence of disease among the patients who underwent
conservative surgery (Table 3). Table 4 shows estimated relative
risk of having recurrence of disease for different combination of
procedure of conservative surgery and histopathological subtype.
For example, the relative risk for a patient receiving cystectomy for
her serous tumour is 4.33 times greater than the risk for a patient
receiving adnectomy for her nonserous tumour.
The clinical and pathological features of the eight patients who
developed recurrence were demonstrated in Table 5. None of these
eight patients died of progression of their disease. Three of the four
serous tumours with recurrence were a noninvasive peritoneal
implant, one of which was diagnosed as a serous adenocarcinoma
at recurrence. The case developed adenocarcinoma in contralateral
ovary 107 months after cystectomy. All mucinous tumours with
recurrence were of intestinal subtype. All patients with recurrence
who were initially treated conservatively are free of disease after
secondary surgical treatment.
DISCUSSION
It has been shown that the 5-year survival rate was 95–97% for
stage I and 65–87% for stages II and III (Trope et al, 2000; Trimble
et al, 2002; Sherman et al, 2004) suggesting that the prognosis for
borderline ovarian tumours depends on extraovarian extension of
the tumour. In addition, prognostic factors included clinical stage,
histopathological subtype, and residual tumour, but the surgical
method was not regarded as a prognostic factor (Trope et al, 2000;
Gilks, 2003). The results of the present study, however, showed
neither the stage nor the histopathological subtype of the disease
was related with long-term prognosis, but showed that disease-free
survival rates were significantly lower in cases managed by
conservative surgery (Figure 1).
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Figure 1 (A) Clinical stages and disease-free survival in patients with
borderline ovarian tumour. There is no significant difference between two
curves. (B) Histological type and disease-free survival in patients with
borderline ovarian tumour. There is significant difference in disease-free
survival between serous and nonserous (mucinous and endometrioid) type
(Po0.05). (C) Surgical procedure and disease-free survival in patients with
borderline ovarian tumour. There is significant difference between two
curves (Po0.05).
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risk factor for recurrence and the risk could be reduced by radical
surgery (Table 2). Because borderline tumours are seen more
frequently in younger females than definitive carcinomas (Harris
et al, 1992), whether conservative surgery is appropriate for
Table 2 Risk factors for recurrence in borderline tumours
Recurrence No recurrence Univariate Multivariate
Factors (n¼8) (n¼94) PP
Mean age (years) 42.2713.7 43.5716.2
Histology, n (%)
Serous 4 (50) 19 (20.2)
Nonserous 4 (50) 75 (79.8) 0.053 0.09
Surgical procedure, n (%)
Radical 2 (33.3) 57 (60.6)
Conservative 6 (66.7) 37 (39.4) 0.05 0.031
Staging laparotomy, n (%)
Staged 3 (37.5) 36 (38.3)
Unstaged 5 (62.5) 58 (61.7) 0.96 0.58
Stage, n (%)
I 7 (87.5) 87 (92.6)
II–IV 1 (12.5) 7 (7.4) 0.61 0.79
Adjuvant chemotherapy, n (%)
Yes 4 (50) 22 (23.4)
No 4 (50) 72 (76.6) 0.098 0.33
Table 3 Risk factors for recurrence in the patients who underwent
conservative surgery for borderline tumours
Recurrence No recurrence Univariate Multivariate
Factors (n¼6) (n¼37) PP
Surgical procedure, n (%)
Cystectomy 3 (50) 5 (13.5)
Adnexectomy 3 (50) 32 (86.5) 0.03 0.047
Staging laparotomy, n (%)
Staged 1 (16.7) 3 (8.1)
Unstaged 5 (83.3) 34 (91.9) 0.51 0.137
Adjuvant chemotherapy, n (%)
Yes 3 (50) 7 (18.9)
No 3 (50) 30 (81.1) 0.095 0.593
Stage, n (%)
Ia 3 (50) 23 (62.2)
Ic 3 (50) 14 (37.8) 0.57 0.198
Histology, n (%)
Serous 3 (50) 6 (16.2)
Non-serous 3 (50) 31 (83.8) 0.059 0.041
Table 4 Relative risk of recurrence in borderline tumours
Histological type
Conservative surgery Nonserous Serous
Adnexectomy 1 2.11
Cystectomy 2.05 4.33
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Zanetta et al (2001) reported that only three of 119 stage I (2.5%)
cases that underwent radical surgery recurred, whereas 20 out of
164 stage I (12.1%) cases that underwent conservative surgery
recurred, with one case resulted in death from the disease. Morice
et al (2001) demonstrated that the majority of recurrent cases,
including stages II and III, were cured completely by subsequent
surgery, and few cases resulted in death. More over, Donnez et al
(2003) reported that although recurrence was commoner in cases
treated by conservative surgery (3 out of 16, 18.7%) than by radical
surgery (0 out of 59, 0%), subsequent treatment resulted in no
tumour-related deaths, and 63.6% of conservative surgery cases
subsequently became pregnant, suggesting that conservative
surgery can be an option for management of borderline malignant
ovarian tumours in young subjects who need to reserve fertility.
However, it is also reported that all of deaths as a result from
recurrence were seen in cases treated by conservative surgery
(Morris et al, 2000; Zanetta et al, 2001). Therefore, it is of quite
importance to investigate underlying risk factors for recurrence
after conservative surgery. As shown in Table 3, we found that
cystectomy and serous tumours were independent risk factors for
recurrence in patients who received conservative surgery. Previous
reports have shown that recurrence after cystectomy did not
necessarily occur ipsilaterally (Morris et al, 2000, 2001; Zanetta
et al, 2001). So it seems that the residual tumour during
cystectomy is solely responsible for recurrence. Then, it may be
rational for young women who wish pregnancy to select
cystectomy as an option if the surgical margin is free of tumour.
However, results by Morice et al (2001) did not support this as
they found that the recurrence rate was high after cystectomy
compared with adnexectomy. Morris et al (2000) also demon-
strated that recurrence was higher in cases treated by cystectomy
rather than by adnexectomy. The present study confirmed this and
further demonstrated for the first time that a difference in
pathohistology affects the recurrence rate. As shown in Table 3, it
was revealed that serous tumour is a significant risk factor for
recurrence in cases managed by conservative surgery. Morris et al
(2000) also showed similar tendency, but they regrettably missed
statistical analysis. As shown in Table 4, the present study clearly
demonstrated that the risk of recurrence when serous tumours
were treated by cystectomy was approximately four times higher
than for adnexectomy of nonserous tumours.
As a prognostic factor for borderline ovarian serous tumours,
the concept of peritoneal implant is attracting attention (Bell et al,
1988). When estimating the prognosis of borderline ovarian serous
tumours, peritoneal lesions should be explored and biopsied at the
time of the surgery – in other words, accurate surgical staging is
required. Clinical stage is one of the most important prognostic
factors in borderline ovarian tumours (Kliman et al, 1986), and an
accurate surgical staging is indispensable for follow-up after
conservative surgery, as well as selecting postoperative therapy.
Winter et al (2002) compared 48 cases that underwent complete
surgical staging, and 45 cases without surgical staging – a higher
stage was found in 17% (8 out of 48) of those assessed by surgical
staging, but there was no difference in recurrence and survival
rates between the groups. Camatte et al (2002) found metastasis to
lymph nodes in 19% (8 out of 42) of cases. All cases with
metastases were seen with borderline ovarian serous tumours
associated with peritoneal dissemination, but no cases resulted in
death – there was no difference in prognosis when compared with
cases without metastases. The presence or absence of a peritoneal
lesion is an important predictive factor of recurrence as well as an
important prognostic factor, and we do not deny the importance of
surgical examination of the abdominal cavity where possible.
However, many reports have indicated that the presence or
absence of lymph node metastasis is not related to the prognosis
for borderline ovarian tumours (Camatte et al, 2002; Winter et al,
2002), and it is still debatable whether or not to perform a biopsy
or dissection of the lymph nodes. As shown in Table 3, the present
study could not show a significant relevance to risk of recurrence.
The limitation of the present study is that surgical staging was not
considered beforehand in all cases so that our data may be biased
in this respect. Further studies using a prospective design with
emphasis on surgical staging are required to investigate the risk of
recurrence in borderline ovarian serous tumours after conservative
surgery. Therefore, it is important that conservative surgery should
only be performed in cases that truly require conservative surgery,
after giving a full explanation of the risk of recurrence.
Barakat et al (1995) reported that cisplatin-based chemotherapy
induced complete remission in six of 23 (26%) advanced cases with
macroscopic diseases, and in 17 of 25 (68%) cases with
microscopic disease, and proposed that adjuvant chemotherapy
could be considered as a therapeutic option although a life-
extension effect of chemotherapy was not clear. In the present
study, the regimen or frequency of chemotherapy used was not
uniform, and differed among institutions, and no relationship was
found between the presence or absence of postoperative adjuvant
chemotherapy and recurrence (Table 2). Kaern et al (1993) showed
that adjuvant chemotherapy did not improve neither recurrence
free survival nor overall survival rate in 364 cases without residual
tumour. Morice et al (2001) demonstrated that postoperative
chemotherapy did not improve the survival rate in 80 cases of
advanced borderline ovarian serous tumour in stages II and III
with extraovarian extension, and that deaths were more closely
related to the treatment than to the tumour. Thus, the efficacy
of chemotherapy for borderline ovarian tumours is not yet
established.
In conclusion, although recurrence was detected in eight out of
102 cases with borderline ovarian tumour that were available for
follow-up, no tumour-related deaths were found, and there was a
favourable long-term prognosis. Although the relative risk of
recurrence is high, conservative surgery appears to be worth trying
to preserve fertility, considering the favourable prognosis. When
considering conservative surgery, special care should be given
when cystectomy is chosen as a surgical procedure or the
histological subtype is borderline serous ovarian tumour. Con-
sensus has not been reached on such issues as to the significance of
surgical staging, the indication for postoperative adjuvant
chemotherapy, or the indications for conservative surgery. To
reinforce the present study results, we expect that a large scaled
prospective clinical study involving many institutions will be
designed to obtain more evidence.
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